Predictions of time to HIV viral rebound following ART suspension that incorporate personal biomarkers
Fig 9
Model-recommended frequency of testing for ATI clinical trials, depending on study objectives, averaged over study population’s HIV CA-RNA levels.
Probability of viral rebound given fixed testing frequencies of every 1, 3, 7, and 14 days, as a function of time since ATI for study participants whose pre-ATI ART regimen (a) excluded and (b) included NNRTIs.